# US 2008/0187588 A1 · Formulations With Controlled Release Of Active Ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187588 A1
- Document ID: US20080187588A1
- Status: Published application
- Kind: A1
- Application number: 11/579,925
- Filed: 2005-05-10
- Published: 2008-08-07
- Earliest claimed: 2004-05-11
- Assignees: Bayer HealthCare LLC
- Inventors: Susanne Zuleger; Peter Serno; Helmut Haning; Kerstin Pauli; Roland Heinig
- Web page: https://patentgrep.com/patent/US20080187588A1

## CPC

- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 9/0004: {Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 9/5042: {Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose}
- A61K 9/5047: {Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose}
- A61K 9/5078: {with drug-free core}
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/10: for impotence
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel pharmaceutical dosage forms with controlled release of active ingredient which comprise the PDE 5 inhibitor vardenafil and/or pharmaceutically acceptable salts, hydrates, solvates and/or polymorphic forms thereof as active ingredient, and to the production thereof. The invention further relates to the use of these novel pharmaceutical dosage forms as medicaments, and to their use for producing medicaments for the treatment and/or prevention of disorders in humans and animals.

## Claims

### Claim 1

Pharmaceutical dosage form with controlled release of active ingredient which comprise the PDE 5 inhibitor vardenafil and/or pharmaceutically acceptable salts and/or hydrates and/or solvates thereof as active ingredient, and which has an average release rate of 5 between 80% in 2 hours and 80% in 24 hours.

### Claim 2 (depends on 1)

Pharmaceutical dosage form according to claim 1 with an average release rate of between 80% in 3 hours and 80% in 20 hours.

### Claim 3 (depends on 1, 2)

Pharmaceutical dosage form according to claim 1 or 2 with an average release rate of between 80% in 3 hours and 80% in 18 hours and with an initial release of less than 65% of the active ingredient in the first 30 minutes of release.

### Claim 4 (depends on 1, 2, 3)

Pharmaceutical dosage form according to at least one of claims 1 to 3, characterized by an initial release of between 0 and 30% of the active ingredient in the first 30 minutes of release.

### Claim 5 (depends on 1, 2, 3)

Pharmaceutical dosage form according to at least one of claims 1 to 3, characterized by an initial release of between 30 and 60% of the active ingredient in the first 30 minutes of release.

### Claim 6 (depends on 1, 2, 3, 4)

Pharmaceutical dosage form according to at least one of claims 1, 2, 3 or 4, characterized by an average release rate of between 80% in 4 hours and 80% in 18 hours and by an initial release of between 0 and 25% of the active ingredient in the first 30 minutes of release.

### Claim 7 (depends on 1, 2, 3, 5)

Pharmaceutical dosage form according to at least one of claims 1, 2, 3 or 5, characterized by an average release rate of between 80% in 3 hours and 80% in 16 hours and by an initial release of between 35 and 60% of the active ingredient in the first 30 minutes of release.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

Pharmaceutical dosage form according to at least one of claims 1 to 7 for oral use.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

Pharmaceutical dosage form according to at least one of claims 1 to 8, characterized by a core which comprises the active ingredient and is enveloped by a membrane which controls the release of the active ingredient.

### Claim 10 (depends on 9)

Pharmaceutical dosage form according to claim 9, characterized in that the release-controlling membrane comprises a film-forming polymer and a plasticizer.

### Claim 11 (depends on 9, 10)

Pharmaceutical dosage form according to claim 9 or 10, characterized in that the release-controlling membrane comprises a film-forming polymer and a pore former.

### Claim 12 (depends on 9, 10, 11)

Pharmaceutical dosage form according to at least one of claims 9 to 11, characterized in that it comprises ethylcellulose and/or polymethacrylates as film-forming polymer.

### Claim 13 (depends on 9, 10, 11, 12)

Pharmaceutical dosage form according to at least one of claims 9 to 12, characterized in that the active ingredient-containing core comprises a pH-modifying substance.

### Claim 14 (depends on 9, 10, 11, 12, 13)

Pharmaceutical dosage form according to at least one of claims 9 to 13, characterized in that the pH-modifying substance is succinic acid, citric acid, tartaric acid or potassium hydrogen tartrate.

### Claim 15 (depends on 9, 10, 11, 12, 13, 14)

Pharmaceutical dosage form according to at least one of claims 9 to 14, characterized in that the release-controlling membrane comprises a polymer resistant to gastric juice.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

Pharmaceutical dosage form according to at least one of claims 1 to 8, characterized by a coated core which comprises one or more swellable excipients which, after penetration in of liquid, cause the coating to split through swelling and volume expansion.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

Pharmaceutical dosage form according to at least one of claims 1 to 8, characterized in that it comprises the active ingredient in a matrix which delivers the active ingredient through diffusion or erosion.

### Claim 18 (depends on 17)

Pharmaceutical dosage form according to claim 17, characterized in that the matrix includes a water-swellable polymer.

### Claim 19 (depends on 17, 18)

Pharmaceutical dosage form according to claim 17 or 18, characterized in that it is a tablet.

### Claim 20 (depends on 17, 18, 19)

Pharmaceutical dosage form according to at least one of claims 17 to 19, characterized in that the water-swellable polymer is hydroxypropylmethylcellulose or hydroxypropylcellulose.

### Claim 21 (depends on 17, 18, 19, 20)

Pharmaceutical dosage form according to at least one of claims 17 to 20, characterized in that the matrix comprises a pH-modifying substance.

### Claim 22 (depends on 17, 18, 19, 20, 21)

Pharmaceutical dosage form according to at least one of claims 17 to 21, characterized in that the pH-modifying substance is succinic acid, citric acid or tartaric acid.

### Claim 23 (depends on 17, 18, 19, 20, 21, 22)

Pharmaceutical dosage form according to at least one of claims 17 to 22, characterized in that the matrix comprises a polymer resistant to gastric juice.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 17)

Pharmaceutical dosage form according to at least one of claims 1 to 8 or 17, characterized in that it comprises a melt extrudate of the active ingredient which is produced by incorporating the active ingredient into a matrix by means of a melting process.

### Claim 25 (depends on 24)

Pharmaceutical dosage form according to claim 24, characterized in that the melt extrudate includes a thermoplastic polymer.

### Claim 26 (depends on 24, 25)

Pharmaceutical dosage form according to claim 24 or 25, characterized in that the melt extrudate comprises a thermoplastic polymer and a plasticizer.

### Claim 27 (depends on 24, 25, 26)

Pharmaceutical dosage form according to at least one of claims 24 to 26, characterized in that the thermoplastic polymer is polyvinylpyrrolidone or hydroxypropylcellulose.

### Claim 28 (depends on 24, 25, 26, 27)

Pharmaceutical dosage form according to at least one of claims 24 to 27, characterized in that the melt extrudate includes a pH-modifying substance.

### Claim 29 (depends on 24, 25, 26, 27, 28)

Pharmaceutical dosage form according to at least one of claims 24 to 28, characterized in that the melt extrudate comprises a polymer resistant to gastric juice.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

Pharmaceutical dosage form according to at least one of claims 1 to 8, characterized in that it is an osmotic medicinal substance release system.

### Claim 31 (depends on 30)

Pharmaceutical dosage form according to claim 30, consisting of:
a core which comprises the active ingredient, where appropriate a hydrophilic polymeric swelling agent and where appropriate a water-soluble substance to initiate osmosis, and where appropriate further pharmaceutically acceptable excipients,
and a shell which consists of a water-permeable material which is impermeable to the components of the active ingredient-containing core, and has at least one orifice through which the ingredients present in the core can be released.

### Claim 32 (depends on 30, 31)

Pharmaceutical dosage form according to claim 30 or 31, which comprises polyethylene oxides, xanthan gum and/or copolymers of vinylpyrrolidone and vinyl acetate.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

Pharmaceutical dosage form according to at least one of claims 1 to 32, which comprises a plurality of identical or different formulation particles as defined in claims 9 to 32.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

Pharmaceutical dosage form according to at least one of claims 1 to 33, which comprises part of the active ingredient in rapid-release form.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

Pharmaceutical dosage form according to at least one of claims 1 to 34, which comprises vardenafil and/or vardenafil in the form of its salts, hydrates, solvates, hydrates of the salts and solvates of the salts, and of the polymorphic, crystalline and amorphous forms respectively belonging thereto.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

Pharmaceutical dosage form according to at least one of claims 1 to 35, which additionally comprises at least one other medicinal substance.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

Pharmaceutical dosage form according to at least one of claims 1 to 36, which comprises from 1 to 100 mg of the active ingredient calculated as vardenafil.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

Pharmaceutical dosage form according to at least one of claims 1 to 37, which comprises from 2 to 50 mg of the active ingredient calculated as vardenafil.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

Pharmaceutical dosage form according to at least one of claims 1 to 38, which includes a matrix which comprises 1 to 30% (m/m) vardenafil hydrochloride trihydrate, 10 to 65% of a water-soluble polymer with a nominal viscosity of at least 50 cP and 10 to 50% (m/m) of an organic acid based on the total mass of the matrix.

### Claim 40 (depends on 39)

Pharmaceutical dosage form according to claim 39, which comprises 2 to 20% (m/m) vardenafil hydrochloride trihydrate, 20 to 55% of a water-soluble polymer with a nominal viscosity of at least 50 cP and 20 to 40% (m/m) of an organic acid based on the total mass of the matrix.

### Claim 41 (depends on 39, 40)

Pharmaceutical dosage form according to claim 39 or 40 in the form of a multilayer or shell/core tablet which includes a rapid-release layer, a rapid-release shell or rapid-release core.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

Use of the PDE 5 inhibitor vardenafil and/or of its pharmaceutically acceptable salts and/or hydrates and/or solvates and of the relevant polymorphic, crystalline and amorphous forms for producing a pharmaceutical dosage form as defined in claims 1 to 41.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

Use of the pharmaceutical dosage forms according to at least one of claims 1 to 41 for the treatment and/or prophylaxis of erectile dysfunction.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

Use of the pharmaceutical dosage form according to at least one of claims 1 to 41 for the treatment and/or prophylaxis of diseases which experience a therapeutic benefit through increasing the cGMP level.
